At present, among some immune checkpoints used for tumor immune escape, the most far-reaching clinical applications are: programmed death receptor1/programmed death ligand1 (PD-1/PD-L1), cytotoxicity T lymphocyte antigen4 (CTAL4) (9). This evidence concerns the gene CD274 and neoplasm.